Multiparametric MRI radiomics for noninvasive prediction of HER2 status in immunohistochemical 2+ breast cancer
Frontiers in Oncology · 14.01.2026 · 15
DOI: 10.3389/fonc.2025.1765392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 14.01.2026. Verfasst von Xiaoguang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Daping Hospital, Army Medical University, Chongqing, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Breast cancer (BC) patients with low expression of human epidermal growth factor receptor 2 (HER2), now classified as HER2-low, may benefit from new novel antibody-drug conjugates, such as trastuzumab deruxtecan. However, patients with immunohistochemistry (IHC) 2+ require further fluorescence in situ hybridization (FISH) to definitively determine HER2 status. Our study aims to explore the feasibility of radiomics models based on multiparametric magnetic resonance imaging (mpMRI) in predicting the HER2 status of IHC 2+ BC patients. Materials and methods 107 IHC 2+ BC patients, which composed of 65 (60.75%) FISH-negative and 42 (39.25%) FISH-positive, were enrolled in the retrospective study and divided into the training set (n = 74) and testing set (n = 33). The clinical and conventional MRI characteristics were used to build a clinical-imaging model. Radiomics features were extracted from T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and DCE phase3 and DCE phase7 in the dynamic contrast-enhanced T1-weighted imaging (DCE-T1WI), and radiomics models were built based on each individual sequence, mpMRI sequences, and a combination of mpMRI sequences with clinical-imaging characteristics. The area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy were calculated. DeLong test was used to determine the differences among various models. p-value <0.05 was considered statistically significant.
Results
The clinical-imaging model achieved AUCs of 0.733 and 0.738 in the training and testing sets. Among the single-sequence radiomics models, the DCE phase7 model achieved the best predictive performance, with AUCs of 0.874 and 0.835 in the training and testing sets. The combined model C, composed of mpMRI model C (DCE phase7 +DWI+T2WI) and clinical-imaging model, showed the best predictive performance, with AUCs of 0.952 and 0.892 in the training and testing sets.
Conclusion
The mpMRI-based radiomics models had potential to noninvasively predict the HER2 status in IHC 2+ BC patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Nuclear Medicine, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Pathology, Daping Hospital, Army Medical University, Chongqing, China.
- School of Electrical and Electronic Engineering, Chongqing University of Technology, Chongqing, China.
Zitieren
APA
Li, X., Dong, Q., Guo, H., Zhang, C., Tian, J., Cheng, C., Zhong, P., Gui, S., Cong, C., & Wang, Y. (2026). Multiparametric MRI radiomics for noninvasive prediction of HER2 status in immunohistochemical 2+ breast cancer. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1765392
Vancouver
Li X, Dong Q, Guo H, Zhang C, Tian J, Cheng C, et al. Multiparametric MRI radiomics for noninvasive prediction of HER2 status in immunohistochemical 2+ breast cancer. Frontiers in Oncology. 2026;15. doi:10.3389/fonc.2025.1765392
BibTeX
@article{Li2026,
author = {Li, Xiaoguang and Dong, Qiujie and Guo, Hong and Zhang, Chunlai and Tian, Jing and Cheng, Cheng and Zhong, Peng and Gui, Shan and Cong, Chao and Wang, Yi},
title = {Multiparametric MRI radiomics for noninvasive prediction of HER2 status in immunohistochemical 2+ breast cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {15},
doi = {10.3389/fonc.2025.1765392}
}
EUVIMED